COMMUNIQUÉS West-GlobeNewswire

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
29/05/2026
Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks throughout the day Approval advances pediatric diabetes care by introducing a new [...]
Ipsen announces the launch of an Employee Shareholding Plan
29/05/2026
Ipsen announces the launch of an employee shareholding plan PARIS, FRANCE, 29 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the launch of an employee shareholding plan. This fifth transaction in the last [...]
Ipsen annonce le lancement d'une opération d’actionnariat salarié
29/05/2026
Ipsen annonce le lancement d'une opération d’actionnariat salarié PARIS, FRANCE, 29 MAI 2026 - Ipsen (Euronext : IPN ; ADR : IPSEY), annonce aujourd’hui le lancement d'une opération d’actionnariat salarié. Cette 5 ème [...]
ALK to present at the Jefferies Global Healthcare Conference in New York
29/05/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company’s Executive Vice President and CFO, Claus Steensen Sølje, is scheduled to present at the 2026 Jefferies Global Healthcare Conference in New York [...]
The Next Great AI Revolution May Be Drug Delivery
29/05/2026
DENVER, May 29, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com ) – When most investors think about artificial intelligence, they picture chatbots, automation platforms, semiconductors, or cloud infrastructure. Yet [...]
BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
29/05/2026
KUALA LUMPUR, Malaysia, May 29, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a technology-focused company advancing innovation across biotechnology, precision [...]
SRx Health Solutions Invests in Uber Technologies, Inc. and Provides Shareholders with Portfolio Update
29/05/2026
Reduced long position in Compass, Inc., reduced short exposure to Bitcoin and added selective hedges in select international markets EMJX stress model turned STRESS from MIXED this week – the first negative market [...]
Cannabix Expands BreathLogix Alcohol Screening Technology into Mining, Municipal and Aviation Sectors in Australia
29/05/2026
VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath devices is [...]
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
29/05/2026
Vancouver, Canada, May 29, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
SkyAI Appoints Veteran Finance Executive Arthur Levine as Chief Financial Officer
29/05/2026
Mission-critical appointment with extensive public company, multinational, and emerging growth experience as SkyAI advances its agentic finance platform Marks the latest step in the Company’s evolution as it continues [...]
Imviva Biotech to Present Data from Clinical Studies of CTA313 and CTD402 Validating its ANSWER™ Allogeneic CAR-T Platform in Pediatric and Adult Patient Populations at EULAR and EHA 2026 Congresses
29/05/2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that it will present data on CTA313, its [...]
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia
29/05/2026
Updated TGA recommendations broaden therapist eligibility, accept a wider range of treatment settings, and reinforce Australia's position as the world's leading commercial market for prescribed psilocybin and MDMA [...]
Sparrow Pharmaceuticals to Present Phase 2a Results for Clofutriben in Type 2 Diabetes at the 2026 American Diabetes Association (ADA) Scientific Session
29/05/2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals , a targeted cardiometabolic therapeutics company, today announced the presentation of results describing Phase 2a efficacy and safety data in patients [...]
New TECVAYLI®▼ (teclistamab) data demonstrate superior progression-free and overall survival versus standard of care as early as first relapse in multiple myeloma
29/05/2026
MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of Johnson & Johnson’s TECVAYLI ® as early as second line 1 TECVAYLI ® delivered deep and durable responses, with nearly two-thirds of [...]
AEON Clinic Redefines Longevity with Premier NAD+ IV Therapy and Premium IV Drips in Dubai
29/05/2026
DUBAI, United Arab Emirates, May 29, 2026 (GLOBE NEWSWIRE) -- AEON Clinic, Dubai’s premier destination for advanced regenerative medicine and holistic wellness located at Atlantis The Royal, is elevating the city’s [...]
Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
29/05/2026
Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances HOUSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“ [...]
Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25
29/05/2026
Brain tissue oxygenation in early stage of stroke with BXT-25 is monitored in real time BOSTON, MASSACHUSETTS, May 29, 2026 (GLOBE NEWSWIRE) -- Bioxytran Inc. (OTCQB: BIXT), a biotechnology company developing [...]
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
29/05/2026
Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D MIAMI, May 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, [...]
Omniscient Secures USD 27.2M Series D to Accelerate Commercialization of AI-Enabled Brain Technology
29/05/2026
Funding to scale FDA-cleared Quicktome® platform and drive next-generation personalized brain care globally SAN FRANCISCO, May 29, 2026 (GLOBE NEWSWIRE) -- Omniscient (o8t®), a pioneer in AI-driven brain analysis [...]

Pages